Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
This page provides an archive of news and press releases related to Centogene N.V. (historically associated with the symbol CNTG). The company has described itself as the essential life science partner for data-driven answers in rare and neurodegenerative diseases, integrating multiomic technologies with the CENTOGENE Biodatabank to support diagnosis and pharmaceutical research.
News items for Centogene cover several themes. These include announcements about large-scale research initiatives such as the Rostock International Parkinson's Disease (ROPAD) Study, which focuses on the genetics of Parkinson’s disease and has generated findings on genetic risk factors and the prevalence of specific variants. Releases also describe collaborations in lysosomal diseases and Gaucher disease, including work with partners like Critical Path Institute and Evotec SE, where CENTOGENE’s data and biomarkers have been used alongside external platforms to identify and characterize potential therapeutic candidates.
Other historical news highlights corporate and financial developments, such as strategic collaborations, joint ventures, financing arrangements, and the company’s strategic alternatives review. A key set of announcements in late 2024 and early 2025 detail the agreement and subsequent closing of the sale of Centogene N.V.’s operating subsidiaries to an affiliate of Charme Capital Partners, shareholder approvals at an Extraordinary General Meeting, and the company’s stated intention to enter dissolution and liquidation following the transaction.
Because Centogene N.V. has reported that, after the sale of its operating subsidiaries, it and its remaining subsidiary will no longer have operations and will enter dissolution and liquidation, the CNTG news flow is best understood as a historical record. Investors and researchers can use this page to review how the company described its multiomic diagnostics, Biodatabank, research collaborations, and the sequence of corporate events leading up to the sale of its operating subsidiaries and planned liquidation.
Centogene N.V (Nasdaq: CNTG) announced on May 15, 2020, that Chief Business Officer Oved Amitay will resign effective May 31, 2020. He will be succeeded by Sun Kim, currently the Chief Strategy and IR Officer. Prof. Arndt Rolfs, CEO, expressed gratitude for Amitay's contributions to the growth of the Pharma business, emphasizing Kim’s extensive experience in strategy and commercial operations as beneficial for future collaborations. Centogene focuses on rare diseases, utilizing a platform with approximately 2.5 billion data points from around 500,000 patients worldwide as of December 31, 2019.
Centogene N.V. (Nasdaq: CNTG) has announced a COVID-19 testing initiative for nursing homes in Mecklenburg-Western Pomerania, Germany. This project, expected to generate €2 to 3 million in contract value, aims to protect vulnerable populations and hasten the return to normalcy. CEO Prof. Arndt Rolfs stated the importance of testing in safeguarding nursing home residents. Centogene specializes in rare diseases, leveraging a vast data repository and collaborating with numerous pharmaceutical partners to enhance drug development.
On May 8, 2020, CENTOGENE (Nasdaq: CNTG) announced it would provide validated SARS-CoV-2 PCR tests to students at Carolinum High School in Neustrelitz, Germany. This initiative aims to facilitate a return to normalcy in education during the COVID-19 pandemic and serves as a model for other schools. The testing will occur twice a week, with results provided the same day, while ensuring ongoing health measures. CENTOGENE's commitment reflects its social responsibility and focus on early diagnosis to curb the virus's spread.
Centogene (Nasdaq: CNTG) has expanded its Senior Leadership Team with the appointment of Angelos Baxevanis as Senior Vice President of Communication and Marketing. With nearly 20 years of experience, Baxevanis will enhance the company's marketing and communication strategies to solidify Centogene’s position as a leader in rare disease solutions. CEO Prof. Arndt Rolfs expressed enthusiasm for Baxevanis's proven track record, indicating a strong commitment to addressing the diagnostic challenges faced by rare disease patients. Centogene utilizes extensive real-world data to improve treatment decisions and expedite orphan drug development.